Back to top

Nektar initiated with a Buy at Canaccord on rezpegaldesleukin potential

As previously reported, Canaccord analyst Edward Nash initiated coverage of Nektar (NKTR) with a Buy rating and $153 price target The Phase 3 progr...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Nektar Therapeutics (NKTR)